Kornimate/medical-research-clean huggingface dataset:
a study of azd4901 in females with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

Summary: to assess the effects of azd4901 when given in multiple doses to females with polycystic ovary syndrome


Eligibility criteria:
inclusion criteria: female patients between the ages of 18 to 45 years (inclusive). suitable veins for cannulation or repeated venipuncture. body mass index (bmi) between 18 and 40 kg/m2 (inclusive). a diagnosis of polycystic ovary disease. amenorrhea or oligomenorrhea (defined as ≤ 6 menses per year). negative serum pregnancy test at screening. negative urine pregnancy test before randomisation. not be breast-feeding. not have been pregnant within the 6 months prior to screening. exclusion criteria: perimenopausal or reached natural menopause, defined as fsh \> 10 iu/l. menstruated within the month prior to the baseline visit. hysterectomy or bilateral oophorectomy or both. clinically relevant disease and abnormalities (past or present), and in particular causes of abnormal vaginal bleeding. withdrawals from oral contraceptives if their lh levels are below 3 iu/l when retested within 7 ± 1 days of the baseline visit.

Keywords: pharmacokinetics, pharmacodynamics, endocrinopathies, pcos, female, hormone, lh
step by step group therapy for bulimia nervosa: effectiveness and mechanisms of change.

Conditions: Bulimia Nervosa

Summary: this a pseudo-randomized clinical trial that examines if a specific group therapy for bn is effective in improving its symptomatology, and what variables mediate such improvements. to do so a sample of 100 patients with bn will be pseudorandomized in a group therapy for bn or in a control waiting list group. patients will be assessed at baseline, at the end of the group therapy and at 2 year follow up.

this is a controlled non randomized study that will compare a group of patients with bn that participate in the sbs group therapy with a group of bn patients who will be in wait list as a control condition. patients for this single center trial will be recruited from the outpatient facility of the hospital de la santa creu i sant pau (barcelona, spain). after assessed for eligibility participants will be given a set of self -report questionnaires. after the questionnaires are completed participants will be allocated to wait list condition or to the treatment arm. time between assessment and starting the sbs group will be a month or least. participants will be administered the same questionnaires the following month after finishing the treatment or after 3 to 4 months after the first assessment for the control condition.

Eligibility criteria:
inclusion criteria: * diagnostic of bulimia nervosa exclusion criteria: * not understanding spanish or catalan language
correction of selenium deficiency has effect on thyroid function

Conditions: Selenium Deficiency

Summary: previous literature has found potential association between selenium deficiency and inactivated glutathione peroxidase and deiodinase, which may contribute to subsequent elevation of t4 and ratio of t4/t3. conduction of a case-control study (id: liuyanping3) has been applied on clinicaltrials.gov to further elucidate effect of selenium deficiency on thyroid function. based on its data, the investigators will perform a randomized, placebo-controlled,single-blinded crossover study on 20 participants with selenium deficiency to verify health consequence of selenium.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of selenium deficiency through serum selenium test in previous phase (id: liuyanping3) of the study * should have stable body weight in the latest 3 months; * should be not prescribed with thyroid hormone replacement therapy * should be without medical history of thyroid surgery or iodine radiotherapy * should have normal ft3, ft4 and tsh. exclusion criteria: * clinical diagnosis of acute critical illness in the latest 1 year * have had weight fluctuation by more than 5% * eating disorders * neuropsychological disorders * allergy to corn or yeast
early salvage therapy for patients with advanced features for biochemical relapse after radical prostatectomy for localized prostate carcinoma in correlation with supposed molecular-genetic parameters of higher aggressiveness

Conditions: Prostate Cancer

Summary: the primary objective of the trial is to compare the impact and safety of delayed salvage therapy (dsrt, i.e., srt initiated at psa values of 0.4-0.5 ng/ml) to those of early salvage therapy (esrt, i.e., at psa levels of 0.2 ng/ml) in patients with biochemical relapse after radical prostatectomy. the secondary objective of the trial is to perform analysis of the subgroups of patients to determine which patients are most likely to benefit from dsrt exploratory objective of the trial is to determine whether selected molecular genetic parameters (172 candidate genes and molecular alterations) and known clinical parameters can be used to identify potential predictors of worse prognosis in patients with known risk factors for relapse after radical prostatectomy, thereby augmenting and refining patient stratification, optimizing their therapy, and clarifying the proper timing of multimodal therapy


Eligibility criteria:
inclusion criteria: * \> 18 years of age * pathologically confirmed invasive prostate carcinoma with minimal 1 risk factor (rf) after radical prostatectomy (rp) * patient refuses the adjuvant therapy after normalization of urinary function within 6 month after rp * signed informed consent to participate in the study and (where necessary) consent to participate in the translational part of the research (not a requirement) * ecog 0 - 1 * pt2 and minimal 1 risk factor (rf): * r1 (psm), and/or * gleason score (4+3=7) 8-10 and/or isup grade group 3-5 * pt3a /pt3b with or without one rf * no evidence of suspicious pelvic lymph nodes by initial diagnostic: cn0 and/or pn0 * no evidence of suspicious distant metastases by initial diagnostic: m0 * patient with decline of psa level to undetectable psa levels (\ 0,2 ng/ml (bcr= biochemical relapse) without any clinical relapse on psma pet/ct * no hormonal therapy prior and /or after the radical prostatectomy * patient suitable and fit for subsequent radiotherapy with high likelihood of good compliance to the follow-up exclusion criteria: * life expectancy (based on charlson comorbidity index) \< 10 years * patient not fit for the therapy * history of other cancer (other than a radically removed non-melanoma skin carcinoma) * previous pelvic irradiation * active immunosuppressive medication * history of hormone therapy prior to randomization * cn1 and/or pn1 and m1 * psa-persistence after rp (psa 12-weeks after rp \> 0.1 ng/ml or no decreasing trend described in inclusion criteria)

Keywords: prostate carcinoma salvage therapy biochemical relapse
effects of 5-aminolevulinic acid on glucose metabolism

Conditions: Type 2 Diabetes on Medication

Summary: this study is designed to evaluate efficacy of 5-aminolevulinic acid in subjects with type 2 diabetes on medication.


Eligibility criteria:
inclusion criteria: * type 2 diabetic patients on medication * hba1c ≤ 9.0% (as jds values, which is equivalent to hba1c ≤ 9.4% as ngsp values) * on stable treatment of diabetes for at least the last 3 months * with permission to attend the clinical trial from the primary doctor exclusion criteria: * on insulin therapy * bmi ≤ 18 kg/m2 or ≥ 30 kg/m2 * history of porphyria, hemochromatosis, or viral hepatitis * pregnant or nursing a child * heart disease * renal or hepatic dysfunction * participation in any clinical trial within 90 days of the commencement of the trial
polycystic ovary syndrome genetics and treatment response

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome (pcos) is the most common endocrine disorder in reproductive age women. women with pcos have a high risk of prediabetes, type 2 diabetes and heart disease. the investigators have found a possible change in the dna (genes of the body that encode all of our traits) that seems to be related to insulin resistance. in this study, the investigators will try to determine whether the change in the gene affects a woman's ability to respond to a common treatment for pcos, metformin. these studies will uncover the change in a gene that might be one of the causes of pcos. discovering this gene will help better understand the diabetes and insulin abnormalities that are common in pcos and will help us to better diagnose and treat pcos to prevent the diabetes in these women.

polycystic ovary syndrome (pcos), which affects 7-10% of reproductive aged women, has traditionally been classified as a reproductive and dermatologic syndrome because of its high rate of infertility and the cosmetic complications of hyperandrogenism. however, it has become increasingly clear that insulin resistance is important in the pathogenesis of the disorder. there are a number of variants that have been determined to be associated with pcos risk. the investigators will determine the effect of these variants on the phenotype and response to treatment in pcos. subjects with pcos will undergo extensive phenotyping including adipose tissue biopsy, dual energy x-ray absorptiometry (dxa, bone density) scan to examine adipose stores, an intravenous glucose tolerance test to study insulin sensitivity and beta cell function, androgen stimulation and inflammatory markers. the phenotyping will be repeated after 3 months of treatment with metformin. the studies will determine whether the genotype at pcos risk variants dictates phenotype and response to treatment with metformin. discovering genes involved in the etiology of pcos will help pull us out of the endless circle that has characterized our understanding of pcos pathophysiology for many years. the proposal also has the potential to illuminate one etiology of insulin resistance, which is present even in lean women with pcos, and the impaired glucose tolerance and diabetes found in over 40% of pcos patients.

Eligibility criteria:
inclusion criteria: * polycystic ovary syndrome * no medications for 1 month * good general health exclusion criteria: * smoker * acute infection or chronic disease * diabetes * trying to get pregnant * bleeding disorders
house dust mite induced inflammasome activation on corticosteroid resistance

Conditions: Allergic Asthma

Summary: in this project, pbmcs will be isolated from hdm allergic and non allergic patient and then stimulated with hdm crude extract. the expression of inflammasome and the correlation of inflammasome activation and steroid resistance will be investigated.


Eligibility criteria:
inclusion criteria: * hdm allergic and non allergic subjects exclusion criteria: * pregnant subject, cancer
ssri and buprenorphine

Conditions: Opiate Dependence; Depression

Summary: this study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to buprenorphine and reduces symptoms of depression for individuals receiving buprenorphine through their medical provider.

participants interested in receiving buprenorphine will be offered the opportunity to enroll in this study. enrolled study participants will complete interviews at baseline and again every two weeks for a total of 8 interviews over 3 months. in this double-blind randomized controlled trial, participants will either receive a placebo or escitalopram (10mg). all participants will also be followed by their buprenorphine clinic medical provider. questions during the face-to-face interviews will assess mood, drug craving, pain, sleep, medication adherence and drug-related experiences. comparison(s): participants randomized into the medication component of the study as compared to participants randomized into the placebo component of the study.

Eligibility criteria:
inclusion criteria: * opiate dependence * ham-d \> 14 exclusion criteria: * no psychiatric contraindications to using escitalopram * no medical contraindications to using escitalopram * methadone dose \< 30 * no current ssri use

Keywords: opiate use depression buprenorphine escitalopram
removal versus non removal of ceserean section scar .

Conditions: Cesarean Wound; Dehiscence

Summary: excision of cs section skin scar and subcutaneous release versus non removal in repeated cs .arandomized controlled trial .

all eligible participants will randimized into two groups ; gruop 1 skin removal in which we will going to remove skin scar gruop 2 skin non removal ;direct open in the middle of the previous scar follow up will be recorded for each participant aphoto will be taken postoperative to score the healing of the wound the follow up will be at one week ,then one month ,then three month acomparison between the two groups will be done .

Eligibility criteria:
inclusion criteria: 1. women with repeated ceserean section 2. pregnant women \>32 wk exclusion criteria: * dm bleeding tendency preeclampsia previous history of wound infection chronic steroid use women refused to participate in randomized clinical trial
normative data for the qmci-tw in a taiwanese sample

Conditions: Postoperative Cognitive Dysfunction

Summary: many perioperative factors have been pointed out as the risk factors for postoperative cognitive dysfunction, which may occur immediately after the surgery, days after the surgery, or months after the surgery. quick mild cognitive impairment screen (qmci) is a sensitive and specific test to differentiate mild postoperative cognitive dysfunction. however, the learning effect have been raised as a bias when we repeated the same test for one person at different timing. thus the study is designed to collected the normative data in series for the qmci-tw in a taiwanese sample.


Eligibility criteria:
inclusion criteria: * adults no less than 20years old exclusion criteria: * pregnant women * patients with respiratory failure \[forced expiratory volume at one second (fev1)/ forced vital capacity (fvc) \< 70 % and fev1 \< 50%\] * patients with heart failure(nyha score =iii、iv) * patients with chronic kidney disease (egfr\< 60 ml.min-1.1.73m-2) * patients with liver failure * patients with ongoing infection * patients have surgery or hospital admission in the past half year
21% hydrochloric acid based versus 6.6 % hydrochloric based micro abrasive kit in management of patients with mild to moderate fluorosis

Conditions: Enamel Discoloration; Fluorosis, Dental

Summary: compare the clinical performance of different concentrations of hydrochloric acid based as micro abrasive kits in management of patients with mild to moderate fluorosis over 6month follow up .

microabrasion is a permanent cosmetic dentistry treatment indeed to preserve the health of all part of any defect in enamel.

Eligibility criteria:
inclusion criteria: patients who wanted to change the appearance of their stained teeth males or females. patients with three or more stained incisors and canines patients willing and able to attend periodic follow-up visits patient concerning with oral health. co-operative patients who show interest to participate in the study. exclusion criteria: patients with known allergic or adverse reaction to the tested materials. smoking habit patients having poor oral hygiene patients with special health care needs or any systemic disease that may affect treatment patients participating in other dental studies. patients suffering from white spot lesion, hypoplasia, amelogenesis imperfecta, dentinogenesis imperfecta, or badly broken and missing teeth due to mih. participants who had a history of dental bleaching.

Keywords: dental fluorosis microabrasion enamel discoloration patient reported outcome measures randomized clinical trial high consentration hydrochloric acid based microabrasive kit(antivet) low consentration hydrochloric acid based microabrasive kit ( opalustre)
pragmatic amiodarone trial to reduce postoperative atrial fibrillation in patients undergoing cardiac surgery

Conditions: Surgery, Cardiac; Atrial Fibrillation

Summary: postoperative atrial fibrillation is quite common after cardiac surgery with up to 1 in 3 patients experiencing this abnormal heart rhythm. amiodarone, a medication commonly used to treat atrial fibrillation, has been previously shown to be an effective prophylactic agent at decreasing the occurrence of postoperative atrial fibrillation in patients who underwent coronary artery bypass surgery. however, despite many studies which have demonstrated its effectiveness, it has not been widely used due to the concern of side effects that can occur such as slow heart rate, low blood pressure, and lung toxicity. we have designed a study to test the effectiveness and safety of a short course of postoperative prophylactic amiodarone for patients undergoing non-coronary artery bypass cardiac surgery. we hypothesize that patients who receive the prophylactic amiodarone will have decreased rates of postoperative atrial fibrillation without significantly increased side effects compared to patients who receive the standard postoperative care after non-coronary artery bypass cardiac surgery.


Eligibility criteria:
inclusion criteria: * \>= 18 years of age * all genders * all non-coronary artery bypass cardiac surgery patients * preoperative normal sinus rhythm exclusion criteria: * pre-existing atrial fibrillation or atrial arrhythmias * pre-existing heart block * cardiogenic shock * sick sinus syndrome * marked sinus bradycardia * preoperative amiodarone use * contraindication to amiodarone use * pr interval \> 240 ms * qtc \> 550 ms * 2nd or 3rd degree heart block * liver impairment (inr \> 1.7, ast/alt \> 2x normal) * uncontrolled hyperthyroidism or hypothyroidism * interstitial lung disease * pregnancy and/or breastfeeding * known hypersensitivity to any components of amiodarone, including iodine * emergent operation * planned maze or pulmonary vein isolation procedure

Keywords: postoperative atrial fibrillation poaf
mild hip dysplasia

Conditions: Hip Dysplasia

Summary: hip dysplasia is a complex problem that exists on a spectrum from mild to severe disease. periacetabular osteotomy (pao) remains the gold standard for most patients with dysplasia; however, the procedure is quite invasive making the decision to proceed in cases of mild disease difficult. hip arthroscopy (ha) is an alternative minimally invasive technique that can be used to address mild dysplasia. nevertheless, ha has less capability for correction and in rare instances can exacerbate instability in the dysplastic hip. there is a paucity of data examining outcomes between these two treatment strategies for this challenging problem.

the bernese periacetabular osteotomy (pao) remains the gold standard for treatment of symptomatic developmental dysplasia of the hip (ddh) in most patients with closed triradiate cartilage. first developed by ganz in 1984, this technique utilizes 4 osteotomies to completely mobilize the acetabular fragment 1. although a technically demanding procedure, it allows optimal correction in all planes and maintains integrity of the posterior column, enabling early weight bearing and mobilization. several groups have confirmed the long-term efficacy of this joint preservation procedure with a recent report from the inventing institution documented impressive survivorship up to 30 years after surgery 2. treatment with pao is more controversial for mild forms of dysplasia where the lateral center-edge angle (lcea) is 18° - 25° and/or the tӧnnis angle is 8° - 15°. in these patients the delta correction is more limited, thus creating a more unpredictable result with equally invasive surgery.

Eligibility criteria:
inclusion criteria: * diagnosis of symptomatic mild ddh * lateral center-edge angle 18° - 25° and/or tӧnnis angle 8° - 15° * skeletally mature * age 18 - 45 * tonnis grade 0 or 1 osteoarthritis (minimal or no arthritis) * ability to receive a standard of care preoperative mri arthrogram of the hip exclusion criteria: * pregnant women * neurogenic dysplasia * legg-calvé-perthes disease * previous surgery about the hip including previous hip arthroscopy to address intra-articular pathology
intra articular injections with platelet rich plasma in patients with juvenile osteochondritis dissecans of the knee

Conditions: Osteochondritis Dissecans

Summary: this study plans to learn more about ways to treat a joint problem in the knee called juvenile osteochondritis dissecans (ocd). the goal of this study is to see if injecting platelet-rich plasma (prp) into the knee can help knee cartilage heal faster, and will try to determine whether the injections lead to improvements in pain, performance of activities of daily living, improvements is sports activities and overall function and symptoms reduction. the investigators will compare prp treatment to conservative therapy.


Eligibility criteria:
inclusion criteria: 1. male or female age 10 - 17 inclusive with open physis confirmed by mri 2. documented symptomatic stable juvenile osteochondritis dissecans of the knee based on mri without changes of osteoarthritis and no prior history of knee surgery. 3. the patient must be able to hold still without sedation for approximately 1 hour and must pass mri screening evaluation for retained metal. 4. patients with di paola stage 1 or 2 lesions exclusion criteria: 1. patients with polyarticular disease. 2. patients with blood disorders (blood disorders (thrombopathy, thrombocytopenia, anemia with hemoglobin \<9g/dl). only those patients with a positive history of blood disorders will have a complete blood count (cbc) performed a week prior to inclusion in the study. 3. patients who had intra-articular treatment with steroids within 3 months 4. patients who are pregnant or nursing at the time of consent. 5. patients with inflammatory arthritic conditions (e.g. rheumatoid arthritis) 6. non-english speaking patients. (scores used for evaluation have not been validated in spanish) 7. patients who had previous knee surgery 8. additional disabilities in any of the lower limbs that would interfere with any of the clinical assessments. 9. chronic use of nsaid (defined as taking non-steroidal anti-inflammatory drug) regularly every week for the last 6 months), steroids or chemotherapy drugs 10. treatment with nsaids within 15 days prior to randomization in this study 11. patients with a bmi over 30. due to the fact that this study utilizes an injection technique which may be inaccurate in obese subjects. 12. patients with a prolongation of bleeding time, e.g. those receiving anticoagulant drug therapy 13. patients with a contraindication to mri including: patients with cardiac pacemaker or non-approved intracranial vascular clip, and those with orthopedic hardware as the resulting artifact can complicate interpretation 14. patients with acute or chronic renal failure 15. patients with a previous anaphylactic reaction to gadolinium enhanced mri. 16. patients with di paola stage 3 or 4 lesions